Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Aura Biosciences (Nasdaq: AURA) closed an underwritten public offering on May 5, 2026, selling 46,099,650 common shares (including full exercise of the underwriters' option) and pre-funded warrants to purchase up to 3,800,000 shares.

Securities sold at $6.00 per share and $5.99999 per pre-funded warrant, producing approximately $299.4 million gross proceeds before underwriting discounts, commissions and offering expenses.

Positive

• Raised approximately $299.4M in gross proceeds
• 46,099,650 common shares issued including full underwriter option exercise
• 3,800,000 pre-funded warrants sold exercisable at $0.00001

Negative

• Gross proceeds stated before underwriting discounts, commissions and offering expenses
• Issuance of common shares and pre-funded warrants increases potential dilution for existing shareholders

News Market Reaction – AURA

-6.85% 3.5x vol

40 alerts

-6.85% Session close to close

+10.0% Peak Tracked

-6.7% Trough Tracked

$611.82M Market Cap

3.5x Rel. Volume

In the May 6 session, AURA declined 6.85%, reflecting a notable negative market reaction. Argus tracked a peak move of +10.0% during that session. Argus tracked a trough of -6.7% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.5x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.8% in the session following this news. A negative reaction despite another capita...

Analysis

The stock moved -6.8% in the session following this news. A negative reaction despite another capital raise would contrast with previous offering announcements that coincided with generally positive moves averaging 12.42%. Selling pressure could reflect concerns about dilution or financing dependence rather than the mechanics of this deal alone. Future sentiment may hinge on successful deployment of proceeds into bel-sar’s Phase 3 program and upcoming data milestones.

Key Figures

Common shares sold: 46,099,650 shares Underwriters’ option shares: 6,508,650 shares Pre-funded warrants: 3,800,000 warrants +4 more

7 metrics

Common shares sold 46,099,650 shares Shares of common stock sold in this public offering

Underwriters’ option shares 6,508,650 shares Additional common shares sold via full option exercise

Pre-funded warrants 3,800,000 warrants Aggregate pre-funded warrants to purchase common stock

Warrant exercise price $0.00001 per warrant Exercise price for each pre-funded warrant

Offering price (stock) $6.00 per share Public offering price for common stock in this deal

Offering price (warrants) $5.99999 per warrant Public offering price for pre-funded warrants

Gross proceeds $299.4 million Approximate gross proceeds before fees and expenses

Previous Offering Reports

4 past events · Latest: May 04 (Neutral)

Same Type Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Equity offering priced	Neutral	+19.1%	Pricing of large stock and pre-funded warrant offering for bel-sar programs.
May 04	Equity offering proposed	Neutral	+19.1%	Announcement of proposed underwritten offering using existing registration.
May 15	Offering pricing 2025	Neutral	+5.7%	Pricing of 2025 stock and warrant financing expected to raise $75M.
May 15	Offering proposed 2025	Neutral	+5.7%	Proposal of 2025 equity and warrant offering under effective shelf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent equity offerings have coincided with positive price reactions, suggesting investors have previously treated capital raises as supportive to the story rather than purely dilutive.

Recent Company History

Over the past year, AURA has repeatedly accessed the equity markets, including offerings in May 2025 and multiple offering announcements on May 4, 2026. Those deals funded bel-sar’s clinical programs and were linked to positive single-day moves of 5–19%. Alongside these raises, the company has reported ongoing progress in its Phase 3 CoMpass trial and maintained guidance for topline data in H2 2027. Today’s closing formalizes the latest, and largest, financing in that sequence.

Key Terms

underwritten public offering, pre-funded warrants, registration statement on Form S-3, Form S-3MEF, +2 more

6 terms

underwritten public offering financial

"today announced the closing of its previously announced underwritten public offering."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registration statement on Form S-3 regulatory

"The offering was made pursuant to the Company’s registration statement on Form S-3 (No. 333-278253)"

A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.

Form S-3MEF regulatory

"and a related registration statement on Form S-3MEF (File No. 333-295515) effective as of May 4, 2026"

A Form S-3MEF is a short-form SEC registration used by already-reporting companies to pre-register medium‑term debt notes, effectively creating a ready-to-use borrowing program. For investors, it matters because it gives the issuer a fast, predictable way to take on new debt — like having a pre-approved business loan — which can change a company’s interest costs, credit risk and capital structure quickly and so may affect bond and stock valuation.

Rule 462(b) regulatory

"filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933, as amended"

Rule 462(b) is an SEC provision that lets an issuer add more securities of the same class to an already-effective registration statement by filing a short post-effective amendment that becomes effective on filing, so the additional securities are immediately registered without redoing the full approval process. For investors this matters because it lets companies and underwriters expand an offering quickly—like adding extra seats to a sold-out show—changing supply and potential dilution that can affect the stock price.

prospectus supplement regulatory

"a final prospectus supplement related to and describing the terms of the offering"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant. The shares of common stock were sold at a public offering price of $6.00 per share and the pre-funded warrants were sold at a public offering price of $5.99999 per share. The gross proceeds to Aura from the offering were approximately $299.4 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities sold in the offering were offered by Aura.

Leerink Partners, TD Cowen and Evercore ISI acted as joint bookrunning managers for the offering. LifeSci Capital also acted as a bookrunning manager in the offering. Citizens Capital Markets acted as a co-manager for the offering.

The offering was made pursuant to the Company’s registration statement on Form S-3 (No. 333-278253), which was previously filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2024 and declared effective by the SEC on April 5, 2024, and a related registration statement on Form S-3MEF (File No. 333-295515) effective as of May 4, 2026 and filed with the SEC pursuant to Rule 462(b) under the Securities Act of 1933, as amended (collectively, the “Registration Statement”), and a final prospectus supplement related to and describing the terms of the offering described above was filed with the SEC on May 5, 2026 and is available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to the offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52^nd Street, 35^th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Aura’s lead candidate, bel-sar (AU-011), is currently in late-stage development for early choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura is headquartered in Boston, MA. Aura’s mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

Investor and Media Contact:

Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com

Source: Aura Biosciences, Inc.

FAQ

How much did Aura Biosciences (AURA) raise in the May 5, 2026 public offering?

Approximately $299.4 million in gross proceeds. According to Aura Biosciences, that figure is before deducting underwriting discounts, commissions and other offering expenses, which will reduce net proceeds to the company.

How many shares did AURA issue in the offering and did underwriters exercise their option?

Aura issued 46,099,650 common shares including the full underwriters' option. According to Aura Biosciences, the total includes 6,508,650 shares sold upon full exercise of the underwriters' option to purchase additional shares.

What are the pre-funded warrants sold by Aura and how many were offered?

The company sold pre-funded warrants for up to 3,800,000 shares at an exercise price of $0.00001. According to Aura Biosciences, those warrants were sold in lieu of common stock to certain investors at $5.99999 each.

At what price were Aura common shares and pre-funded warrants sold in the offering?

Common shares were sold at $6.00 per share and pre-funded warrants at $5.99999 per share. According to Aura Biosciences, those were the public offering prices for the securities sold.

Who managed Aura Biosciences' May 2026 offering and where was it registered?

The offering was led by Leerink Partners, TD Cowen and Evercore ISI with LifeSci Capital and Citizens Capital Markets participating. According to Aura Biosciences, it was conducted under Form S-3 registration statements declared effective by the SEC.